Helsinn Achieves Carbon Neutrality

Helsinn Achieves Carbon Neutrality Lugano, Switzerland, December 6, 2021 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, today announces that it has achieved carbon neutrality for the first time. Since 2012, Helsinn…

Read More

Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12

First and only neutralizing antibody therapy for this age group SHANGHAI, China, Dec. 06, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced…

Read More